BRIEF-MAIA Biotechnology Announces Positive Survival Updates In Phase 2 Study Of Thio In Non-Small Cell Lung Cancer

Reuters09-10

Sept 10 (Reuters) - Maia Biotechnology Inc :

* MAIA BIOTECHNOLOGY ANNOUNCES POSITIVE SURVIVAL UPDATES IN PHASE 2 STUDY OF THIO IN NON-SMALL CELL LUNG CANCER

* MAIA BIOTECHNOLOGY INC - 16 PATIENTS SURPASSED 12-MONTH SURVIVAL FOLLOW-UP

* MAIA BIOTECHNOLOGY INC - THIO FOLLOWED BY LIBTAYO GENERALLY WELL-TOLERATED

* MAIA BIOTECHNOLOGY INC - EXPECTS TO RELEASE FULL EFFICACY RESULTS OF THIO-101 THIS YEAR

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466436363?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466436363","market":"us","top_or_hot":-1,"title":"BRIEF-MAIA Biotechnology Announces Positive Survival Updates In Phase 2 Study Of Thio In Non-Small Cell Lung Cancer","media":"Reuters","content":"<html><body><p>Sept 10 (Reuters) - Maia Biotechnology Inc   :</p><p>   * MAIA BIOTECHNOLOGY ANNOUNCES POSITIVE SURVIVAL UPDATES IN PHASE 2 STUDY OF THIO IN NON-SMALL CELL LUNG CANCER</p><p>   * MAIA BIOTECHNOLOGY INC - 16 PATIENTS SURPASSED 12-MONTH SURVIVAL FOLLOW-UP</p><p>   * MAIA BIOTECHNOLOGY INC - THIO FOLLOWED BY LIBTAYO GENERALLY WELL-TOLERATED</p><p>   * MAIA BIOTECHNOLOGY INC - EXPECTS TO RELEASE FULL EFFICACY RESULTS OF THIO-101 THIS YEAR</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-MAIA Biotechnology Announces Positive Survival Updates In Phase 2 Study Of Thio In Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-MAIA Biotechnology Announces Positive Survival Updates In Phase 2 Study Of Thio In Non-Small Cell Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-10 19:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 10 (Reuters) - Maia Biotechnology Inc   :   * MAIA BIOTECHNOLOGY ANNOUNCES POSITIVE SURVIVAL UPDATES IN PHASE 2 STUDY OF THIO IN NON-SMALL CELL LUNG CANCER   * MAIA BIOTECHNOLOGY INC - 16 ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2466436363","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466436363","pubTimestamp":1725967024,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 10  - Maia Biotechnology Inc   :   * MAIA BIOTECHNOLOGY ANNOUNCES POSITIVE SURVIVAL UPDATES IN PHASE 2 STUDY OF THIO IN NON-SMALL CELL LUNG CANCER   * MAIA BIOTECHNOLOGY INC - 16 PATIENTS SURPASSED 12-MONTH SURVIVAL FOLLOW-UP   * MAIA BIOTECHNOLOGY INC - THIO FOLLOWED BY LIBTAYO GENERALLY WELL-TOLERATED   * MAIA BIOTECHNOLOGY INC - EXPECTS TO RELEASE FULL EFFICACY RESULTS OF THIO-101 THIS YEARSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MAIA":"MAIA Biotechnology Inc."},"translate_title":"BRIEF-MAIA Biotechnology宣布Thio治疗非小细胞肺癌2期研究的积极生存更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAIA":1},"content_text":"Sept 10 (Reuters) - Maia Biotechnology Inc   :   * MAIA BIOTECHNOLOGY ANNOUNCES POSITIVE SURVIVAL UPDATES IN PHASE 2 STUDY OF THIO IN NON-SMALL CELL LUNG CANCER   * MAIA BIOTECHNOLOGY INC - 16 PATIENTS SURPASSED 12-MONTH SURVIVAL FOLLOW-UP   * MAIA BIOTECHNOLOGY INC - THIO FOLLOWED BY LIBTAYO GENERALLY WELL-TOLERATED   * MAIA BIOTECHNOLOGY INC - EXPECTS TO RELEASE FULL EFFICACY RESULTS OF THIO-101 THIS YEARSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466436363"}